ERIMOS - Key Persons

Job Titles:

• Board Director
• CFO
• Member of the Ang 's Holding Company
• Specialist

Alex Hung is a specialist in investment strategy planning, as well as in the financial management field. He has full knowledge of the complete set of the company's Trade Secret regarding the manufacturing methods of Nordihydroguaiaretic Acid (NGDA), which is the principal compound of Terameprocol, and other related intellectual properties of Erimos Pharmaceutical, LLC.

Job Titles:

• Scientific Advisor

Dr, Von Hoff is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, AZ. He also serves as Chief Scientific Officer for US Oncology and Scottsdale Clinical Research Institute.

Job Titles:

• CEO
• President
• Scientific Advisor / Management Team

Dr. Mohrland, was previously CEO and President of Erimos and now serves as a scientific advisor. He has extensive experience in the pharmaceutical industry building and managing global organizations focused on the development and commercialization of oncology and other therapeutic products. Dr. Mohrland served as Executive Vice President for GMP Companies, Inc., a global company focused on the development and commercialization of pharmaceuticals and other medical products. Prior to GMP, he spent more than 21 years with Pharmacia Corporation, Pharmacia and Upjohn, Inc. and the Upjohn Company, where he held a number of executive positions, including Vice President of Scientific, Professional and Government Operations, and Vice President of Medical Operations and Scientific Affairs. Dr. Mohrland has served on several boards, including serving as Vice Chairman of Florida's biotechnology industry organization. He has held several academic appointments at major universities. Dr. Mohrland received his PhD in pharmacology from Washington State University, and was a Postdoctoral Fellow at the University of Iowa. He has authored numerous scientific and medical publications and been a member of several scientific and medical societies.

Job Titles:

• CEO
• Chairman of the Board
• Co - Founder

Jeffrey Khoo is a co-founder of Erimos Pharmaceuticals and serves as Executive Chairman of the Board. Jeffrey has more than 30 years of multi-industry experience including life sciences, medical devices, semiconductors, investment management, and property development. He founded 3V SourceOne Capital Pte Ltd. (Singapore), a venture capital firm based in Silicon Valley and Singapore. He is a member of the board of directors of several real estate development companies in Malaysia, Hong Kong and China. Jeffrey was a member of Eli Lilly & Company's Strategic Planning Team in the Medical Instrument Division. He is a graduate of the National University of Singapore with a First Class Honors Degree in Electrical Engineering. His MBA in finance was attained at the Haas School of Business, University of California, Berkeley. He is a member of the CFA Institute.

Job Titles:

• Chief
• Scientific Advisor
• Co - Founder and Chief Scientific Advisor

Ru Chih Huang, PhD, is a co-founder and Chief Scientific Advisor at Erimos Pharmaceuticals. She is the lead inventor of Erimos' technology. Dr. Huang is currently a professor in the Department of Biology at The Johns Hopkins University. Dr. Huang's scientific publications, addressing the function of chromosomal proteins, messenger RNA, and RNA polymerases, represent the major aspect of her earlier contributions to the field of molecular biology. Her more recent research focuses on the understanding of viral gene transcription, replications, and oncogenic development in humans. The discoveries of mutation-insensitive antiviral and anticancer compounds, the derivatives of plant lignan NDGA, have led to a series of recent patents and publications.

Job Titles:

• Vice President - Clinical and Regulatory Affairs

Dr. Glenn earned his PhD in Physiology at University of Illinois Champaign-Urbana and joined the Biochemistry research staff at University of Texas MD Anderson Hospital as an Assistant Biochemist. Dr. Glenn has directed three Phase III and numerous Phase I and II US and International corporate clinical studies and has served as a clinical and regulatory consultant to numerous clients. He has twice served on the program committee of the Regulatory Affairs Professional Society Annual Meeting. His academic research experience includes 6 years on the research staff University of Texas MD Anderson Hospital. As an Inventor he has 15 issued patents, most of these patents have been commercially licensed. He is an author of 27 scientific and medical publications and numerous abstracts.